5 Psychedelics Show Similar Brain Patterns in 500+ Scans

Scientists just made a major breakthrough in understanding how psychedelic drugs might help treat mental health conditions.

Researchers at McGill University led the largest analysis of its kind, combining data from 11 brain imaging studies across five countries. They examined more than 500 brain scans from 267 people who took psychedelics including psilocybin, LSD, mescaline, DMT, and ayahuasca.

The surprising discovery? Despite having different chemical makeups, all five drugs created nearly identical patterns of brain activity.

"The most surprising finding is that, despite the discrepancies in the pharmacology of these drugs, there is a common denominator of how they affect the human brain," says study co-author Danilo Bzdok, a neuroscientist at McGill University. The findings were published in Nature Medicine on April 6.

The research challenges what scientists previously believed about psychedelics. Many researchers thought these drugs "dissolved" or broke down brain networks during a trip.

Instead, the team found that psychedelics actually boost communication between different brain regions. Brain networks involved in advanced thinking became much more connected to areas that process sight, sound, and movement in people who took the drugs.

Harvard Medical School psychiatric neuroscientist Shan Siddiqi calls it "the largest study of its kind so far." Previous research on psychedelics typically involved only small groups of participants, making it hard to draw solid conclusions.

Why This Inspires

Dozens of clinical trials have already shown promise for using psychedelics to treat depression, anxiety, and addiction. This new research provides the clearest picture yet of how these substances actually work in the brain.

Understanding the shared brain signature across different psychedelics could dramatically speed up drug development. Instead of testing each substance separately, researchers can now design new treatments based on this common pattern of brain activity.

The team analyzed brain scans from studies conducted in the United Kingdom, Switzerland, the Netherlands, the United States, and Brazil. This international collaboration helped ensure the findings apply broadly across different populations and research methods.

"This will inform future drug design for this potentially very important category of drugs for the future of mental health," says Bzdok.

The research marks a turning point from fragmented, small studies to comprehensive science that could transform mental healthcare for millions of people worldwide.